China’s Clover Biopharmaceuticals has initiated a phase 1 clinical trial of its COVID-19 vaccine candidate SCB-2019 in Australia.

The study will evaluate SCB-2019 with adjuvants from GlaxoSmithKline and Dynavax. It is expected to enroll 150 patients.

The company anticipates preliminary results from the trial in August and hopes to begin a global phase 2/3 trial by the end of the year.